Terumo-MicroVention’s FRED X Flow Diverter Used in First U.S. Case

Terumo subsidiary MicroVention completed the first U.S. clinical case using its next-generation FRED X flow diverter at Philadelphia’s Thomas Jefferson University Hospital. The FRED X device earned U.S. Food Administration (FDA) approval last September.
 
FRED X’s self-expanding braided nitinol mesh helps redirect blood flow and promote aneurysm occlusion. It’s designed to reduce the device material’s thrombogenicity and boost blood vessel healing.
 
According to the company, FRED X offers the smallest and largest flow diversion systems in the U.S.
 
“FRED X represents an important advancement in flow diversion therapy. The X Technology surface treatment applied to the FRED X Device is designed to reduce material thrombogenicity and has further increased the deliverability of the FRED X,” Dr. Stavropoula Tjoumakaris, Director, Endovascular Surgery and Cerebrovascular Neurosurgery Fellowship at Thomas Jefferson University Hospital, and principal investigator of the FRED X (post approval) study, told the press. “We are excited to be the first center in the U.S. to have clinical experience using the FRED X device and look forward to a clinical study on the benefits of X Technology.”
 
Since receiving CE mark approval in 2013, the FRED device has been used on tens of thousands of patients.
 
“At MicroVention, we continue to enhance our product portfolio to make meaningful improvements in patient care,” said Carsten Schroeder, president and CEO of MicroVention. “Surface treatment technologies, such as the FRED X device, represent the next frontier in neurovascular therapy, and MicroVention is proud to be able to offer the first of several devices incorporating our X Technology to physicians and patients in the U.S.”